A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1
- Conditions
- Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS)as defined by the International Prognostic Scoring System (IPSS).MedDRA version: 9.1Level: LLTClassification code 10028532Term: Myelodysplasia
- Registration Number
- EUCTR2007-002212-26-FR
- Lead Sponsor
- Groupe Francophone des Myélodysplasies
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
1.Patient has MDS including the following FAB sub-types: refractory anemia with blast excess (RAEB) ,transformed refractory anemia with blast excess (RAEB-t) and non proliferative Chronic MyeloMonocytic Leukemias (WBC below 13G/l).
2.Patient has a IPSS score > 1. 5 (INT-2 and high risk categories).
3.Patient is male or female, and = 18 years of age on day of signing informed consent.
4.Patient has an Eastern Cooperative Oncology Group (ECOG) performance s
tatus =2 (See Appendix 6.1).
5.Patient has recovered from toxicities due to prior therapy (less than grade 2) except for cytopenia
6.Patient must have adequate organ function as indicated by the following laboratory values:
?Serum creatinine or calculated creatinine clearancea < 2 mg/dl or = 60 mL/min for patients with creatinine levels > 1.5 X institutional ULN Hepatic
?Serum total bilirubin = 2.5 X ULN or direct bilirubin = ULN for patients with total bilirubin levels = 2 mg/dL.
?AST (SGOT) and ALT (SGPT)= 2.5 times ULN
?Alkaline Phosphatase = 5 X ULN If > 2.5 X ULN, then liver fraction
should be = 2.5 X ULN
(Creatinine clearance should be calculated per institutional standard)
7.Patient is known to not be refractory to platelet transfusions.
8.Female patient of childbearing potential has a negative serum pregnancy test (ß-hCG) within 72 hours prior to receiving the first dose of vorinostat and or Ara-C . Female patient is not actively breastfeeding at the time of study entry.
9.Female patient is either post-menopausal, free from menses for > 2 years, surgically sterilized or willing to use 2 adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from becoming pregnant throughout the study, starting with Visit 1.
10.Male patient agrees to use an adequate method of contraception for the duration of the study. Men should be advised not to father a child while receiving vorinostat and for 1 month post study.
11.Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study.
12.Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1.Patient had prior treatment with an HDAC inhibitor (e.g., depsipeptide or NSC-630176, MS 275, LAQ-824, PXD-101, LBH589, MGCD0103, CRA024781, etc). Patients who have received compounds with HDAC inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not enroll in this study. Patients who have received such compounds for other indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout period.
2.Patient has been previously treated with low dose (20 mg/m2 SC daily) Ara-C for MDS within 3 months of beginning this study.
3.Patient with RAEB-2 or RAEB-T eligible for intensive chemotherapy followed or not by allogeneic stem cell transplantation
4.Patient has active and uncontrolled infection
5.Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance.
6.Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug.
7.Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy.
8.Patient has clinically active hepatitis B or hepatitis C infection.
9.Patient has a known allergy or hypersensitivity to any component of vorinostat or Ara-C.
10.Patient with a currently active second malignancy, other than nonmelanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a currently active malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for >5 years or are considered by their physician to be at less than 30% risk of relapse.
11.Patient has received growth factors such as epoetin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic treatment, an interval of 3 months is required.
12.Patient is on any systemic steroids that have not been stabilized to the equivalent of = 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs
13.Patients with clinical evidence of CNS leukemia.
14.Patient has a history of GI surgery or other procedures that might interfere with the absorption or swallowing of the study drugs.
15.Patient is unable to take and/or tolerate oral medications on a continuous basis.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method